por
Shah, Tina,
Engmann, Jorgen,
Dale, Caroline,
Shah, Sonia,
White, Jon,
Giambartolomei, Claudia,
McLachlan, Stela,
Zabaneh, Delilah,
Cavadino, Alana,
Finan, Chris,
Wong, Andrew,
Amuzu, Antoinette,
Ong, Ken,
Gaunt, Tom,
Holmes, Michael V.,
Warren, Helen,
Davies, Teri-Louise,
Drenos, Fotios,
Cooper, Jackie,
Sofat, Reecha,
Caulfield, Mark,
Ebrahim, Shah,
Lawlor, Debbie A.,
Talmud, Philippa J.,
Humphries, Steve E.,
Power, Christine,
Hypponen, Elina,
Richards, Marcus,
Hardy, Rebecca,
Kuh, Diana,
Wareham, Nicholas,
Ben-Shlomo, Yoav,
Day, Ian N.,
Whincup, Peter,
Morris, Richard,
Strachan, Mark W. J.,
Price, Jacqueline,
Kumari, Meena,
Kivimaki, Mika,
Plagnol, Vincent,
Dudbridge, Frank,
Whittaker, John C.,
Casas, Juan P.,
Hingorani, Aroon D.
Publicado 2013
“…Using a new high-resolution custom single nucleotide polymorphism (SNP) array (Metabochip) incorporating dense coverage of genomic regions linked to cardiometabolic disease, the
University College-London School-Edinburgh-Bristol (UCLEB) consortium of highly-phenotyped population-based prospective studies, aims to: (1) fine map functionally relevant SNPs; (2) precisely estimate individual absolute and population attributable risks based on individual SNPs and their combination; (3) investigate mechanisms leading to altered risk factor profiles and CVD events; and (4) use Mendelian randomisation to undertake studies of the causal role in CVD of a range of cardiovascular biomarkers to inform public health policy and help develop new preventative therapies.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online
Artículo
Texto